Lung cancer: moving forward with tailored strategies

The Lancet Oncology

Volumn 9, Issue 12, 2008, Pages 1116-1117

  Barlesi, Fabrice ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; PEMETREXED; PLATINUM COMPLEX;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; GENE MUTATION; GENETIC MARKER; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 56449114914     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70290-0     Document Type: Letter

References (13)

1. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., and Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 2926-2936
2. Pujol J.L., Barlesi F., and Daurès J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 51 (2006) 335-345
3. Kosmidis P.A., Kalofonos H.P., Christodoulou C., et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19 (2008) 115-122
4. Greco F.A., Spigel D.R., Kuzur M.E., et al. Paclitaxel/carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer 8 (2007) 483-487
5. Comella P., Filippelli G., De Cataldis G., et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18 (2007) 324-330
6. Kubota K., Kawahara M., Ogawara M., et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 9 (2008) 1135-1142
7. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52 (2006) 155-163
8. Fidias P., Dakhil S., Lyss A., et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival. Proc Am Soc Clin Oncol 25 suppl (2007) LBA7516
9. Hida T., Okamoto I., Kahii T., et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJOG). Proc Am Soc Clin Oncol 26 suppl (2008) LBA8012
10. Ciuleanu T., Brodowicz T., Belani C., et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. Proc Am Soc Clin Oncol 26 suppl (2008) A8011
11. Takeuchi T., Tomida S., Yatabe Y., et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathological behaviours. J Clin Oncol 24 (2006) 1679-1688
12. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 (2008) 1160-1174
13. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991